Director Of Stryker Sold $96.79M In Stock
📉 Director Ronda E Stryker sold 310,000 shares of Stryker (NYSE: SYK) on May 28, according to an SEC Form 4 filing.
💰 The total value of the insider sale was $96,792,668 at the time of execution.
📈 Stryker's stock is trading at $308.67 and rose 0.34% during Friday's morning session.
📊 Over a three-month period ending March 31, 2026, the company reported revenue growth of approximately 2.63%.
⚠️ This revenue growth rate trails behind the average among peers in the Health Care sector.
💳 Stryker's debt-to-equity ratio stands at 0.64, which is notably higher than the industry average.
🏢 The company maintains a market capitalization that surpasses industry standards, indicating a robust market position.
📝 Insider transactions are legally required to be disclosed via Form 4 filings within two business days of the trade.
🤔 Insider sales do not necessarily signal a bearish stance and can be motivated by various personal or financial factors.
🦴 Stryker designs and markets medical equipment including hip and knee replacements, orthopedic robotics, and operating room equipment.
🌍 Roughly one-fourth of Stryker's total revenue currently comes from outside the United States.
💵 The company boasts a high gross margin of 63.29%, reflecting superior cost management compared to peers.
📉 Current earnings per share (EPS) is $1.95, which is significantly higher than the industry average.
📈 The current P/E ratio of 35.61 is below industry norms, suggesting potential undervaluation.
📉 Conversely, the P/S ratio of 4.71 is above industry norms, reflecting an elevated valuation based on sales performance.
🔢 A high EV/EBITDA ratio of 20.14 positions the company as more valued compared to industry benchmarks.
📊 Transaction codes in Form 4 filings use 'S' for sales, 'P' for purchases, and 'C' for option conversions.
🏛️ Under Section 12 of the Securities Exchange Act of 1934, insiders include officers, directors, or beneficial owners holding more than ten percent of equity.
- Stryker's shares are actively trading at $308.67, experiencing a gain of 0.34% during Friday's morning session.
- The company achieved a revenue growth rate of approximately 2.63% as of March 31, 2026, indicating a substantial increase in top-line earnings.
- Stryker maintains a high gross margin of 63.29%, reflecting superior cost management and profitability compared to its peers.
- The company demonstrates robust bottom-line performance with a current EPS of $1.95, which is significantly higher than the industry average.
- With a P/E ratio of 35.61, Stryker's valuation is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
- Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment.
- Roughly one-fourth of Stryker's total revenue currently comes from outside the United States, demonstrating strong international market presence.
- Director Ronda E Stryker executed a substantial insider sell of $96.79M worth of shares on May 28, which may signal concerns about future stock performance despite management's stated neutrality.
- Stryker's revenue growth rate of approximately 2.63% trails behind the average among peers in the Health Care sector, indicating slower top-line expansion relative to competitors.
- The company's debt-to-equity ratio stands at 0.64, which is notably higher than the industry average and raises concerns about financial leverage and reliance on borrowed funds.
- Stryker's current P/S ratio of 4.71 is above industry norms, reflecting an elevated valuation that could present downside risk if sales growth does not accelerate to justify the premium.
- The company's EV/EBITDA ratio of 20.14 positions it as more valued compared to industry benchmarks, suggesting potential overvaluation relative to earnings power.
